Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Shares Outstanding (Weighted Average) (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $144.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 4.68% year-over-year to $144.4 million; the TTM value through Dec 2025 reached $144.4 million, up 4.68%, while the annual FY2025 figure was $144.4 million, 4.68% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $144.4 million in Q4 2025 per MRVI's latest filing, roughly flat from $144.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $144.7 million in Q3 2025 and bottomed at $96.6 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $130.2 million, with a median of $131.9 million recorded in 2023.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 1008.98% in 2021, down 61.94% in 2021.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $114.8 million in 2021, then rose by 14.6% to $131.5 million in 2022, then increased by 0.28% to $131.9 million in 2023, then grew by 4.54% to $137.9 million in 2024, then rose by 4.68% to $144.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $144.4 million in Q4 2025, $144.7 million in Q3 2025, and $144.2 million in Q2 2025.